Preliminary evidence indicated that CRNDE could interact with chromatin-modifying complexes in the epigenetic regulation of gene expression, and may enhance glioma development and malignancy via the mTOR, insulin/IGF, or EGFR signaling pathways, as well as by regulating the expression of miR-186 or miR-384 [15–19]. Here, MTOR is linked to central nervous system cancer.